Citations 2
Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services
Top, Karina A. , Chen, Robert T. , Carleton, Bruce , Creech, C. Buddy , Kochhar, Sonali , Gutu, Kimberley , Cutland, Clare , Levy, Ofer , Ozonoff, Al , Crawford, Nigel W. , Poland, Gregory A.
Clinical Infectious Diseases | June 10, 2022 | Volume: 75 | Issue: Supplement_1 | Pages: S11-S17
AbstractWithin 2 years after the start of the coronavirus disease 2019 (COVID-19) pandemic, novel severe acute respiratory syndrome coronavirus 2 vaccines were developed, rigorously evaluated in large phase 3 trials, and administered to more than 5 billion individuals globally. However, adverse events of special interest (AESIs) have been described post-implementation, including myocarditis after receipt of messenger RNA (mRNA) vaccines and thrombosis with thrombocytopenia syndrome after receipt of adenoviral vector vaccines. AESIs are rare (<1 to 10/100 000 vaccinees) and less frequent than COVID-19 complications, though they have associated morbidity and mortality. The diversity of COVID-19 vaccine platforms (eg, mRNA, viral vector, protein) and rates of AESIs both between and within platforms (eg, higher rate of myocarditis after mRNA-1273 vs BNT162b2 vaccines) present an important opportunity to advance vaccine safety science. The International Network of Special Immunization Services has been formed with experts in vaccine safety, systems biology, and other relevant disciplines to study cases of AESIs and matched controls to uncover the pathogenesis of rare AESIs and inform vaccine development.
Phosphoric Metabolites Link Phosphate Import and Polysaccharide Biosynthesis for Candida albicans Cell Wall Maintenance
Liu, Ning‐Ning , Acosta‐Zaldívar, Maikel , Qi, Wanjun , Diray‐Arce, Joann , Kelly, R, Yuan, Min , Lasky‐Su, Jessica , Köhler, Julia R. , Walker, Louise A , Kottom, Theodore J. , Lasky-Su, Jessica , Asara, John M. , Levy, Ofer , Limper, Andrew H. , Gow, Neil A. R.
mBio | March 16, 2020 | Volume: 11 | Issue: 2 | Pages: No page available
Candida species cause hundreds of thousands of invasive infections with high mortality each year. Developing novel antifungal agents is challenging due to the many similarities between fungal and human cells. Maintaining phosphate balance is essential for all organisms but is achieved completely differently by fungi and humans. A protein that imports phosphate into fungal cells, Pho84, is not present in humans and is required for normal cell wall stress resistance and cell wall integrity signaling in C. albicans . Nucleotide sugars, which are phosphate-containing building block molecules for construction of the cell wall, are diminished in cells lacking Pho84. Cell wall-constructing enzymes may be slowed by lack of these building blocks, in addition to being inhibited by drugs. Combined targeting of Pho84 and cell wall-constructing enzymes may provide a strategy for antifungal therapy by which two sequential steps of cell wall maintenance are blocked for greater potency.